| Dendreon Receives European Patent Covering PROVENGE(R) and Company's ...
SEATTLE, Jan. 15 /PRNewswire-FirstCall/ -- Dendreon Corporation (NASDAQ: DNDN) today announced that the company has been granted a broad European patent covering the company's lead product candidate PROVENGE(R) (sipuleucel-T), the Company's investigational active cellular immunotherapy for the treatment of advanced prostate cancer. European patent No. 0 870 022 B1 covers the composition of matter of PROVENGE as well as the company's other active cellular immunotherapy (ACI) product candidates, such as NEUVENGE(TM) (lapuleucel-T), which utilize Dendreon's Antigen Delivery Cassette(TM) technology. The patent also covers methods of activating antigen presenting cells in vitro with certain fusion proteins developed by Dendreon, including the fusion protein that is used in PROVENGE. "The approval of this broad patent covering PROVENGE and our other active cellular immunotherapies in Europe is an important milestone for the company," stated Mitchell H.
Obesity Heightens Risk Of Death From Prostate Cancer
Overweight or obese men, according to a new US study, are at greater risk of dying from prostate cancer after treatment than men who are thin. The study, conducted by Dr. Jason Efstathiou and colleagues, published in the journal Cancer, says that overweight or obese men are at a substantially higher risk of death within five years of diagnosis. Overweight men with some extra fat had a 52 percent higher risk of death from locally advanced prostate cancer, the study reports, while obesity more than doubled the likelihood at 64 percent. The study followed 788 patients diagnosed with advanced prostate cancer over a period of eight years, examining the relationship between BMI (body mass index) and mortality. Of the randomized patient pool, 241 were considered at normal body weight, 402 were overweight, and 145 were clinically obese.
ArcMesa Educators Announces First Interdisciplinary Prostate Cancer ...
MONROW TOWNSHIP, N.J., Oct. 29 /PRNewswire/ -- ArcMesa Educators, a multi- accredited provider of award winning continuing education courses, is proud to announce its first annual Interdisciplinary Prostate Cancer Congress (IPCC) taking place in March 2008. This unique congress seeks to foster a paradigm shift to an integrated prostate cancer care team approach among two physician groups actively involved in treatment, namely the oncologist and the urologist. It will be part of a broadening initiative of medical education programming focused on the same theme by identifying and assessing rapid advancements in therapeutics and new treatment modalities with the goal of improved patient outcomes. IPCC also marks another bold step in ArcMesa Educators' strategic realignment with its dedicated focus to provide cutting edge information in an environment and format conducive to the educational needs of physicians.
|
